Ad
related to: actual risk test for asthma icd 10
Search results
Results From The WOW.Com Content Network
A bronchial challenge test is a medical test used to assist in the diagnosis of asthma. [1] The patient breathes in nebulized methacholine or histamine. Thus the test may also be called a methacholine challenge test or histamine challenge test respectively. Both drugs provoke bronchoconstriction, or narrowing of the airways.
Sensitizer-induced occupational asthma is an immunologic form of asthma which occurs due to inhalation of specific substances (i.e., high-molecular-weight proteins from plants and animal origins, or low-molecular-weight agents that include chemicals, metals and wood dusts) and occurs after a latency period of several weeks to years. [1]
to assess of impairment from occupational asthma [8] to identify those at risk from pulmonary barotrauma while scuba diving [8] to conduct pre-operative risk assessment before anaesthesia or cardiothoracic surgery [8] to measure response to treatment of conditions which spirometry detects [8] to diagnose the vocal cord dysfunction.
Very severe acute asthma (termed "near-fatal" as there is an immediate risk to life) is characterised by a peak flow of less than 33% predicted, oxygen saturations below 92% or cyanosis (blue discoloration, usually of the lips), absence of audible breath sounds over the chest ("silent chest" : wheezing is not heard because there is not enough ...
Medication challenge tests, such as the methacholine challenge test, have a lower sensitivity for detection of exercise-induced bronchoconstriction in athletes and are also not a recommended first-line approach in the evaluation of exercise-induced asthma. [13] Mannitol inhalation [14] [15] has been recently approved for use in the United States.
Bronchial hyperresponsiveness is a hallmark of asthma but also occurs frequently in people with chronic obstructive pulmonary disease (COPD). [2] In the Lung Health Study, bronchial hyperresponsiveness was present in approximately two-thirds of patients with non-severe COPD, and this predicted lung function decline independently of other ...
The post bronchodilator test (Post BD), also commonly referred to as a reversibility test, is a test that utilizes spirometry to assess possible reversibility of bronchoconstriction in diseases such as asthma.
The strongest risk factor for developing asthma is a history of atopic disease; [66] with asthma occurring at a much greater rate in those who have either eczema or hay fever. [80] Asthma has been associated with eosinophilic granulomatosis with polyangiitis (formerly known as Churg–Strauss syndrome), an autoimmune disease and vasculitis . [ 81 ]